title: [The efficacy and safety of activated vitamin D for CKD-MBD].
abstract: Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.
authors: Clinical Pharmacotherapeutics I, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
authors: Nobuki
authors: N
authors: Hayakawa
authors: Division of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan.
authors: Atsushi
authors: A
authors: Suzuki
mesh_terms: D015519:Bone Density; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D006435:Renal Dialysis; D014807:Vitamin D / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014807:Vitamin D